Invasive lobular carcinoma (ILC) accounted for 11% of breast cancers in the United States between 2017 and 2021, with incidence rising nearly 3% annually across all racial and ethnic groups. The study found that ILC was most often diagnosed in older patients and presented with larger, hormone receptor–positive, HER2-negative tumors. Although seven-year survival rates were similar to those for invasive ductal carcinoma, 10-year survival was lower for regional and distant disease. Researchers projected approximately 33,600 ILC cases in 2025. Rachel A. Giaquinto, MPH, of the American Cancer Society, noted, “ILC has unique characteristics that can contribute to delayed detection, resistance to therapy, and poorer prognosis for advanced disease.”

Source: Cancer